Is gut microbiome a predictive marker to response to immune checkpoint inhibitors?

Immunotherapy

Volumn 9, Issue 11, 2017, Pages 865-866

  Saleh, Khalil ^a   Khalife Saleh, Nadine ^a   Kourie, Hampig Raphael ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Gut microbiome; Immune checkpoint inhibitors; Predictive marker

Indexed keywords

ANTIBIOTIC AGENT; ATEZOLIZUMAB; BETA LACTAM ANTIBIOTIC; CHECKPOINT KINASE INHIBITOR; COLISTIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA; IMIPENEM; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR MARKER; ANTIINFECTIVE AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; BACTERIAL COLONIZATION; BACTEROIDALES; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BLADDER CARCINOMA; BURKHOLDERIA CEPACIA; CANCER IMMUNOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; CLOSTRIDIALES; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; FAECALIBACTERIUM PRAUSNITZII; FECAL MICROBIOTA TRANSPLANTATION; FIRMICUTES; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GERMFREE MOUSE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INTESTINE FLORA; MALIGNANT NEOPLASM; MELANOMA; METASTATIC MELANOMA; MISMATCH REPAIR; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; POPULATION ABUNDANCE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RENAL CELL CARCINOMA; SARCOMA; SPECIES DIVERSITY; TH1 CELL; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; ANIMAL; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; GASTROINTESTINAL TRACT; IMMUNOLOGY; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 85029577344     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2017-0090     Document Type: Editorial

References (9)

1. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
2. Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol. Immunother. CII. 66(5), 551-564 (2017).
3. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16(5), 275-287 (2016).
4. Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front. Microbiol. (2016). www.ncbi.nlm.nih.gov/pmc/articles/PMC4709861
5. Vétizou M, Pitt JM, Daillere R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264), 1079-1084 (2015).
6. PittJM,Vétizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology 6(1), e1132137 (2017).
7. Chaput N, Lepage P, Coutzac C et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(6), 1368-1379 (2017).
8. Wargo JA, Gopalakrishnan V, Spencer C et al. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. J. Clin. Oncol. 35(15 Suppl.), 3008-3008 (2017).
9. Derosa L, Routy B, Mezquita L et al. Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. J. Clin. Oncol. 35(15 Suppl.), 3015-3015 (2017).